Coated stent assembly and coating materials

• US 20060140867A1
• Filed: 05/13/2005
• Published: 06/29/2006
• Est. Priority Date: 12/28/2004
• Status: Abandoned Application

• Current Assignee: Biophan Technologies Incorporated
• Original Assignee: Biophan Technologies Incorporated
• Inventors: Gray, Robert W., Wang, Xingwu, Greenwald, Howard J., Helfer, Jeffrey L.
• Application Number:
  US11/128,591
• Publication Number:
  US 20060140867A1
• Time in Patent Office: Days
• US Class Current: 424/9.320
• CPC Class Codes: A61K 49/1821 coated or functionalised microparticles or nanoparticles
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

A high magnetic susceptibility nanomagnetic material that may be attached to recognition molecules and other therapeutic biological materials so as to be targeted to specific biologic tissues, thereby enabling the presence of the targeted tissue to be detected under magnetic resonance imaging with much greater sensitivity. Also a stent coated with such nanomagnetic material to enable artifact free imaging of such stent under magnetic resonance imaging.

Claims

1. A MRI contrast enhancing material comprised of nanomagnetic particles having a particle size less than 100 nanometers, a coercive magnetic force of from about 1 to about 200 Oersteds, a remnant magnetization of from about 10 to about 10,000 Gauss, and a saturation magnetization of from about 100 to about 24,000 Gauss.

2. The MRI contrast enhancing material as recited in claim 1, wherein said nanomagnetic particles have a particle size distribution such that at least about 50 percent of said nanomagnetic particles have an average size of from about 3 to about 10 nanometers.

3. The MRI contrast enhancing material as recited in claim 1, wherein said nanomagnetic particles have a particle size distribution such that at least about 60 percent of said nanomagnetic particles have an average size of from about 6 to about 10 nanometers.

4. The MRI contrast enhancing material as recited in claim 1, wherein said nanomagnetic particles have a particle size distribution such that at least about 80 percent of said nanomagnetic particles have an average size of from about 6 to about 10 nanometers.

5. The MRI contrast enhancing material as recited in claim 1, wherein said nanomagnetic particles have a coercive force of from about 10 to about 120 Oersteds.

6. The MRI contrast enhancing material as recited in claim 5, wherein said nanomagnetic particles have a coercive force of from about 20 to about 110 Oersteds.

7. The MRI contrast enhancing material as recited in claim 1, wherein said nanomagnetic particles have a remnant magnetization of from about 1,000 to about 8,000 Gauss.

8. The MRI contrast enhancing material as recited in claim 7, wherein said nanomagnetic particles have a remnant magnetization of from about 2,000 to about 7,500 Gauss.

9. The MRI contrast enhancing material as recited in claim 1, wherein said nanomagnetic particles have a saturation magnetization of from about 10,000 to about 21,000.

10. The MRI contrast enhancing material as recited in claim 1, wherein said nanomagnetic particles have a relative magnetic permeability of from about 1 to about 500,000.

11. The MRI contrast enhancing material as recited in claim 10, wherein said nanomagnetic particles have a relative magnetic permeability of from about 1.5 to about 260,000.

12. The MRI contrast enhancing material as recited in claim 11, wherein said nanomagnetic particles have a relative magnetic permeability of from about 1.5 to about 2000.

13. The MRI contrast enhancing material as recited in claim 1, wherein said nanomagnetic particles are comprised of at least one of three distinct elemental moieties, moiety A, moiety B, and moiety C.

14. The MRI contrast enhancing material as recited in claim 13, wherein moiety A is magnetic and is chosen from the group consisting of iron, nickel, cobalt, alloys thereof, and mixtures thereof, moiety B is non-magnetic and is chosen from the group consisting of silicon, aluminum, boron, platinum, tantalum, palladium, yttrium, zirconium, titanium, calcium, berylium, barium, silver, gold, indium, lead, tin, antimony, germanium, gallium, tungsten, bismuth, strontium, magnesium, and zinc, and moiety C is chosen from the group consisting of oxygen, nitrogen, carbon, fluorine, chlorine, hydrogen, helium, neon, argon, krypton, and xenon.

15. The MRI contrast enhancing material as recited in claim 14, wherein the molar ratio of moiety A to (moiety A+moiety C) is from about 1 to about 99 mole percent.

16. The MRI contrast enhancing material as recited in claim 15, wherein the molar ratio of moiety A to (moiety A+moiety C) is from about 10 to about 90 mole percent.

17. The MRI contrast enhancing material as recited in claim 16, wherein the molar ratio of moiety A to (moiety A+moiety C) is from about 40 to about 60 mole percent.

18. The MRI contrast enhancing material as recited in claim 14, wherein the molar ratio of moiety A to (moiety A+moiety B+moiety C) is from about 1 to about 99 mole percent.

19. The MRI contrast enhancing material as recited in claim 18, wherein the molar ratio of moiety A to (moiety A+moiety B+moiety C) is from about 10 to about 90 mole percent.

20. The MRI contrast enhancing material as recited in claim 19, wherein the molar ratio of moiety A to (moiety A+moiety B+moiety C) is from about 30 to about 60 mole percent.

21. The MRI contrast enhancing material as recited in claim 14, wherein the molar ratio of moiety B to (moiety A+moiety B+moiety C) is from about 1 to about 99 mole percent.

22. The MRI contrast enhancing material as recited in claim 21, wherein the molar ratio of moiety B to (moiety A+moiety B+moiety C) is from about 10 to about 40 mole percent.

23. The MRI contrast enhancing material as recited in claim 14, wherein the molar ratio of moiety C to (moiety A+moiety B+moiety C) is from about 1 to about 99 mole percent.

24. The MRI contrast enhancing material as recited in claim 23, wherein the molar ratio of moiety C to (moiety A+moiety B+moiety C) is from about 10 to about 50 mole percent.

25. The MRI contrast enhancing material as recited in claim 14, wherein said moiety A is iron and said moiety B is aluminum.

26. The MRI contrast enhancing material as recited in claim 25, wherein said moiety C is nitrogen.

27. A stent comprising:

a base substrate having a surface, said surface having an exterior section contiguous with an interior section;

a plurality of layered coatings disposed on at least a portion of said surface, at least one of said plurality of layered coatings being comprised of a nanomagnetic material, said nanomagnetic material comprised of nanomagnetic particles having a particle size less than 100 nanometers, a coercive magnetic force of from about 1 to about 200 Oersteds, a remnant magnetization of from about 10 to about 10,000 Gauss, and a saturation magnetization of from about 100 to about 24,000 Gauss.

28. The stent as recited in claim 27, wherein said nanomagnetic particles have a particle size distribution such that at least about 50 percent of said nanomagnetic particles have an average size of from about 3 to about 10 nanometers.

29. The stent as recited in claim 27, wherein said nanomagnetic particles have a particle size distribution such that at least about 60 percent of said nanomagnetic particles have an average size of from about 6 to about 10 nanometers.

30. The stent as recited in claim 27, wherein said nanomagnetic particles have a particle size distribution such that at least about 80 percent of said nanomagnetic particles have an average size of from about 6 to about 10 nanometers.

31. The stent as recited in claim 27, wherein said nanomagnetic particles have a coercive force of from about 10 to about 120 Oersteds.

32. The stent as recited in claim 31, wherein said nanomagnetic particles have a coercive force of from about 20 to about 110 Oersteds.

33. The stent as recited in claim 27, wherein said nanomagnetic particles have a remnant magnetization of from about 1,000 to about 8,000 Gauss.

34. The stent as recited in claim 33, wherein said nanomagnetic particles have a remnant magnetization of from about 2,000 to about 7,500 Gauss.

35. The stent as recited in claim 27, wherein said nanomagnetic particles have a saturation magnetization of from about 10,000 to about 21,000.

36. The stent as recited in claim 27, wherein said nanomagnetic particles have a relative magnetic permeability of from about 1 to about 500,000.

37. The stent as recited in claim 36, wherein said nanomagnetic particles have a relative magnetic permeability of from about 1.5 to about 260,000.

38. The stent as recited in claim 37, wherein said nanomagnetic particles have a relative magnetic permeability of from about 1.5 to about 2000.

39. The stent as recited in claim 27, wherein said nanomagnetic particles are comprised of at least one of three distinct elemental moieties, moiety A, moiety B, and moiety C.

40. The stent as recited in claim 39, wherein moiety A is magnetic and is chosen from the group consisting of iron, nickel, cobalt, alloys thereof, and mixtures thereof, moiety B is non-magnetic and is chosen from the group consisting of silicon, aluminum, boron, platinum, tantalum, palladium, yttrium, zirconium, titanium, calcium, berylium, barium, silver, gold, indium, lead, tin, antimony, germanium, gallium, tungsten, bismuth, strontium, magnesium, and zinc, and moiety C is chosen from the group consisting of oxygen, nitrogen, carbon, fluorine, chlorine, hydrogen, helium, neon, argon, krypton, and xenon.

41. The stent as recited in claim 40, wherein the molar ratio of moiety A to (moiety A+moiety C) is from about 1 to about 99 mole percent.

42. The stent as recited in claim 41, wherein the molar ratio of moiety A to (moiety A+moiety C) is from about 10 to about 90 mole percent.

43. The stent as recited in claim 42, wherein the molar ratio of moiety A to (moiety A+moiety C) is from about 40 to about 60 mole percent.

44. The stent as recited in claim 40, wherein the molar ratio of moiety A to (moiety A+moiety B+moiety C) is from about 1 to about 99 mole percent.

45. The stent as recited in claim 44, wherein the molar ratio of moiety A to (moiety A+moiety B+moiety C) is from about 10 to about 90 mole percent.

46. The stent as recited in claim 45, wherein the molar ratio of moiety A to (moiety A+moiety B+moiety C) is from about 30 to about 60 mole percent.

47. The stent as recited in claim 40, wherein the molar ratio of moiety B to (moiety A+moiety B+moiety C) is from about 1 to about 99 mole percent.

48. The stent as recited in claim 47, wherein the molar ratio of moiety B to (moiety A+moiety B+moiety C) is from about 10 to about 40 mole percent.

49. The stent as recited in claim 40, wherein the molar ratio of moiety C to (moiety A+moiety B+moiety C) is from about 1 to about 99 mole percent.

50. The stent as recited in claim 49, wherein the molar ratio of moiety C to (moiety A+moiety B+moiety C) is from about 10 to about 50 mole percent.

51. The stent as recited in claim 40, wherein said plurality of layered coatings comprises a first layer coated with a second layer, wherein in said first layer said moiety A is absent, said moiety B is aluminum, and said moiety C is nitrogen, wherein in said second layer said moiety A is iron, said moiety B aluminum, and said moiety C is nitrogen.

52. The stent as recited in claim 51, wherein said first layer has a thickness of from about 400 to about 700 nanometers and said second layer has a thickness of from about 100 to about 2000 nanometers.

53. The stent as recited in claim 52, wherein said second layer has a thickness of from about 400 to about 1000 nanometers.

54. The stent as recited in claim 51, wherein said second layer is comprised of from about 1 to about 39 weight percent of iron, by total weight of iron and aluminum.

55. The stent as recited in claim 54, wherein said second layer is further comprised of 0.1 moles of nitrogen.

56. The stent as recited in claim 54, wherein said second layer is further comprised of 0.2 moles of nitrogen.

57. The stent as recited in claim 54, wherein said second layer is comprised of from about 10 to about 30 weight percent of iron, by total weight of iron and aluminum.

58. The stent as recited in claim 57, wherein said second layer is further comprised of 0.1 moles of nitrogen.

59. The stent as recited in claim 57, wherein said second layer is further comprised of 0.2 moles of nitrogen.

60. The stent as recited in claim 40, wherein said plurality of layered coatings comprises a first layer coated with a second layer coated with a third layer, wherein in said first layer and in said third layer said moiety A is absent, said moiety B is aluminum, and said moiety C is nitrogen, wherein in said second layer said moiety A is iron, said moiety B aluminum, and said moiety C is nitrogen.

61. The stent as recited in claim 60, wherein said first layer and said third layer have a thickness of from about 400 to about 700 nanometers and said second layer has a thickness of from about 100 to about 2000 nanometers.

62. The stent as recited in claim 61, wherein said second has a thickness of from about 400 to about 1000 nanometers.

63. The stent as recited in claim 60, wherein said second layer is comprised of from about 1 to about 39 weight percent of iron, by total weight of iron and aluminum.

64. The stent as recited in claim 63, wherein said second layer is further comprised of 0.1 moles of nitrogen.

65. The stent as recited in claim 63, wherein said second layer is further comprised of 0.2 moles of nitrogen.

66. The stent as recited in claim 60, wherein said second layer is comprised of from about 10 to about 30 weight percent of iron, by total weight of iron and aluminum.

67. The stent as recited in claim 66, wherein said second layer is further comprised of 0.1 moles of nitrogen.

68. The stent as recited in claim 66, wherein said second layer is further comprised of 0.2 moles of nitrogen.

69. The stent as recited in claim 27, wherein said plurality of layered coatings is disposed only on portions of said exterior section of said surface.

70. The stent as recited in claim 27, wherein said plurality of layered coatings is disposed continuously only on said exterior section of said surface.

71. The stent as recited in claim 27, wherein said plurality of layered coatings is disposed only on portions of said interior section of said surface.

72. The stent as recited in claim 27, wherein said plurality of layered coatings is disposed continuously only on said interior section of said surface.

73. The stent as recited in claim 27, wherein said plurality of layered coatings is disposed continuously on said surface.